COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
THERANEXUS JOINS UP WITH SYNERLAB TO PREPARE THE COMMERCIALIZATION OF ITS PEDIATRIC FORMULATION IN NIEMANN-PICK TYPE C DISEASE
Theranexus partners with Synerlab to produce oral solution of miglustat for Niemann-Pick type C disease, aiming for EMA approval and commercialization by 2026. Novel pediatric formulation Mig-OS provides new therapeutic option for NPC patients -
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Theranexus publishes its cash position as of 30 June 2024 and presents an update on the progress of Batten-1
Biopharmaceutical company Theranexus announces implementation of new equity line to finance Phase III trial for Batten-1 drug in juvenile Batten disease. Update on Batten-1 program included
